頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Overview 9
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Comparative Analysis 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics under Development by Companies 11
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Products under Development by Companies 16
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Companies Involved in Therapeutics Development 18
Advaxis, Inc. 18
Amgen Inc. 19
AVEO Pharmaceuticals, Inc. 20
Critical Outcome Technologies Inc. 21
Daiichi Sankyo Company, Limited 22
Genentech, Inc. 23
Glycotope GmbH 24
Immunovative Therapies, Ltd. 25
Laboratoires Pierre Fabre SA 26
Mabion SA 27
MedImmune, LLC 28
Merck & Co., Inc. 29
Novartis AG 30
Oncolytics Biotech Inc. 31
Ono Pharmaceutical Co., Ltd. 32
Panacea Biotec Limited 33
PCI Biotech AS 34
Shionogi & Co., Ltd. 35
Symphogen A/S 36
VentiRx Pharmaceuticals, Inc. 37
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ADXS-HPV – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AlloVax – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alpelisib – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bleomycin sulfate – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cetuximab biobetter – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cetuximab biosimilar – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cetuximab biosimilar – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cetuximab biosimilar – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
COTI-2 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
duligotuzumab – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
durvalumab – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
durvalumab + tremelimumab – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ficlatuzumab – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
futuximab – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LJM-716 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
motolimod – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
nivolumab – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
patritumab – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pelareorep – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pembrolizumab – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
S-488210 – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
vinflunine ditartrate – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Recurrent Head and Neck Cancer Squamous Cell Carcinoma – Recent Pipeline Updates 98
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects 137
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Discontinued Products 138
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 139
Disclaimer 140